Welcome to our dedicated page for bluebird bio news (Ticker: $BLUE), a resource for investors and traders seeking the latest updates and insights on bluebird bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect bluebird bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of bluebird bio's position in the market.
2Flo Ventures announces the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. She has nearly two decades of experience in the biopharmaceutical industry, including roles at Chinook Therapeutics and Otsuka Pharmaceuticals. Dr. Jones-Burton's achievements include a $3.2 billion acquisition by Novartis and multiple industry awards. Her appointment aims to enhance 2Flo's portfolio, which includes companies like Cancer IQ and Vivacelle Bio. Dr. Jones-Burton's expertise aligns with 2Flo's mission of advancing health equity and supporting innovative healthcare solutions.
bluebird bio has appointed O. James Sterling as its new Chief Financial Officer (CFO), effective June 10, 2024. Sterling, who previously served as CFO at Renalytix plc, brings extensive experience in healthcare and capital markets. He succeeds Chris Krawtschuk, who played a pivotal role in improving the company's cash flow and financial stability. Sterling's appointment comes as bluebird bio faces the task of restating its financial statements for 2022 and 2023, which will delay its 2023 Annual Report and Q1 2024 Form 10-Q filings. This restatement is not expected to affect the company’s cash or revenue.
bluebird bio, Inc. (NASDAQ: BLUE) reported strong first quarter 2024 results with a net revenue of $18.6 million. The company anticipates a total of 85 to 105 patient starts for its FDA approved therapies in 2024. Despite a delay in filing financial statements due to a restatement, bluebird bio remains confident in its financial position.
bluebird bio, Inc. (Nasdaq: BLUE) will discuss its first quarter 2024 results and business updates on May 9 at 8:00 a.m. ET. The company will also participate in investor conferences on May 16 and June 12. Investors can access the live webcasts on bluebird bio's website.
bluebird bio, Inc. announced the completion of the first commercial cell collection for LYFGENIA gene therapy, a one-time treatment for sickle cell disease. LYFGENIA was FDA-approved in December 2023 and is the most extensively studied gene therapy for the disease. The cells were collected at Children’s National Hospital in Washington, DC, marking a significant milestone in the treatment of sickle cell disease.
bluebird bio, Inc. (Nasdaq: BLUE) received a notice from Nasdaq due to the delayed filing of its Annual Report on Form 10-K for 2023. The company has until June 24, 2024, to submit a compliance plan. This delay is caused by the need to restate financial statements but is not expected to impact cash position or revenue.
